Jupiter Neurosciences, Inc. has a market cap of $131.5 million and recently completed an IPO underwritten by Dominari and Revere Securities.
The company focuses on developing JOTROL, a resveratrol-based product aimed at treating neuro-inflammation. This product uses patented micellar technology to improve the absorption of resveratrol. Manufacturing has been completed in Florida, and each softgel capsule contains 100mg of resveratrol.
JOTROL is being evaluated for various rare diseases, particularly Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, MELAS, as well as Parkinson’s Disease and early Alzheimer’s. They plan to use IPO proceeds for a Phase II clinical trial of JOTROL in Parkinson’s patients and to establish a market presence in Southeast Asia.
Recent studies indicate that JOTROL may provide better therapeutic effects with fewer side effects compared to existing resveratrol products. The company has completed a Phase I study that successfully met its objectives. Additionally, there’s strong interest in JOTROL from Asian organizations, partly due to the growing use of resveratrol in traditional medicine.
Jupiter Neurosciences, founded in 2016, is based in Jupiter, Florida, and currently has four employees. For more information, visit their website or call (561) 406-6154.
Receive daily news and ratings for Jupiter Neurosciences Inc. by entering your email below: Subscribe to MarketBeat.com’s free daily newsletter.
`
